Rxivist logo

Differential Antiviral Activities of RSV Inhibitors in Human Airway Epithelium

By Carmen Mirabelli, Martine Jaspers, Mieke Boon, Mark Jorissen, Mohamed Koukni, Dorothee Bardiot, Patrick Chaltin, Arnaud Marchand, Johan Neyts, Dirk Jochmans

Posted 19 Jan 2018
bioRxiv DOI: 10.1101/250639 (published DOI: 10.1093/jac/dky089)

We report the use of reconstituted 3D-human airway epithelium cells of bronchial origin (HuAEC) in an air-liquid interface to study respiratory syncytial virus (RSV) infection and to assess the efficacy of RSV inhibitors in (pre-)clinical development. RSV-A replicates efficiently in HuAEC and viral RNA is shed for weeks after infection. RSV infection reduces the ciliary beat frequency of the ciliated cells as of 4 days post infection, with complete ciliary dyskinesia observed by day 10. Treatment with RSV fusion inhibitors resulted in an antiviral effect only when added at the time of infection. In contrast, the use of replication inhibitors (both nucleoside and non-nucleosides) elicited a marked antiviral effect even when start of treatment was delayed until one or even three days after infection. Levels of the inflammation marker RANTES (mRNA) increased ~200-fold in infected-untreated cultures (at three weeks post infection), but levels were comparable to those of uninfected cultures in the presence of PC-876, a RSV-replication inhibitor, demonstrating that an efficient antiviral treatment inhibits virus induced inflammation in this model. Overall, HuAEC offer a robust and physiologically relevant model to study RSV replication and to assess the efficacy of antiviral compounds.

Download data

  • Downloaded 485 times
  • Download rankings, all-time:
    • Site-wide: 45,341 out of 119,012
    • In microbiology: 2,830 out of 9,401
  • Year to date:
    • Site-wide: 87,872 out of 119,012
  • Since beginning of last month:
    • Site-wide: 110,428 out of 119,012

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News